Shuttle Pharmaceuticals Holdings (SHPH) Cash & Equivalents (2021 - 2026)

Shuttle Pharmaceuticals Holdings has reported Cash & Equivalents for 6 years, with the latest figure at $1.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 75.85% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 75.85% decrease from a year earlier, with the FY2025 full-year figure at $334005.0, down 82.61% from the prior year.
• Cash & Equivalents was $1.1 million for Q1 2026 at Shuttle Pharmaceuticals Holdings, up from $334005.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $9.1 million in Q3 2022, with the low at $156656.0 in Q3 2024.
• Average Cash & Equivalents over 5 years is $3.8 million, with a median of $2.9 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 6191.01% in 2022, then slumped 95.97% in 2024.
• Over 5 years, Cash & Equivalents stood at $8.4 million in 2022, then slumped by 65.7% to $2.9 million in 2023, then tumbled by 33.49% to $1.9 million in 2024, then tumbled by 82.61% to $334005.0 in 2025, then soared by 226.33% to $1.1 million in 2026.
• The last three Cash & Equivalents figures came in at $1.1 million (Q1 2026), $334005.0 (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.